SEC Company Response from GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — Jun 17, 2008
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: June 17, 2008 · CIK: 0001133416 · Accession: 0001193125-08-134822
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-150898
Letter
Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Pro-Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-150898)
Dear Mr. Abero:
Pro-Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) be declared effective at 4:30 p.m. (Washington, D.C. time) on Thursday, June 19, 2008, or as soon as practicable thereafter. An oral request for acceleration of effectiveness may be made in the future. The Registrant is aware of its obligations under the Securities Act of 1933, as amended.
In connection with the Registrant’s request for acceleration of effectiveness of the Registration Statement on Form S-3, the Registrant acknowledges that:
•
should the Securities and Exchange Commission (the “SEC”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the SEC from taking any action with respect to the filing;
•
the action of the SEC or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert the declaration of effectiveness as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact the undersigned at (617) 559-0033 or Jonathan C. Guest of Greenberg Traurig LLP at (617) 310-6066.
Sincerely,
PRO-PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request PRO-PHARMACEUTICALS, INC. 7 Wells Avenue Newton, MA 02459 June 17, 2005 By Fax (202-772-9217) and by EDGAR Mr. Sebastian Gomez Abero Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Pro-Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-150898) Dear Mr. Abero: Pro-Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) be declared effective at 4:30 p.m. (Washington, D.C. time) on Thursday, June 19, 2008, or as soon as practicable thereafter. An oral request for acceleration of effectiveness may be made in the future. The Registrant is aware of its obligations under the Securities Act of 1933, as amended. In connection with the Registrant’s request for acceleration of effectiveness of the Registration Statement on Form S-3, the Registrant acknowledges that: • should the Securities and Exchange Commission (the “SEC”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the SEC from taking any action with respect to the filing; • the action of the SEC or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert the declaration of effectiveness as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States. If you have any questions regarding this request, please contact the undersigned at (617) 559-0033 or Jonathan C. Guest of Greenberg Traurig LLP at (617) 310-6066. Sincerely, PRO-PHARMACEUTICALS, INC. By: /s/ Anthony D. Squeglia Name: Anthony D. Squeglia Title: Chief Financial Officer